Originated from pharmaceuticals · Expert in medical beauty
Appeared on the international stage Started the internationalization process
Yaohai Novagen Biotechnology Co., Ltd., a company that independently develops new medical beauty raw materials and active skin care raw materials using synthetic biology technology, was invited to participate in [FCE Cosmetique Brazil International Beauty and Medical Packaging Expo], this exhibition was held in the Pan-American Exhibition Center in Sao Paulo, the largest and most prosperous city in Brazil, South America. The recombinant type III humanized collagen raw materials and recombinant botulinum toxin technology promoted by Yaohai Novagen Biological have been recognized and paid attention to by international peers and beauty lovers, opening the internationalization pace of Yaohai Novagen Biological's medical beauty business!
Concentrate on scientific research Make safe and effective products
Based on the powerful technology platform of its parent company Yaohai Bio, Yaohai Novagen Bio adheres to the corporate philosophy of "originating from pharmaceuticals and being good at medical beauty", and insists on providing the industry with safe and effective products, so that those seeking beauty can solve skin problems with confidence. The key layouts include recombinant collagen platform, recombinant botulinum toxin platform and active peptide raw materials.
1. Raw material 1 - recombinant type III humanized collagen
It has an exclusive core patent, carefully selects highly hydrophilic and highly active fragments, with a total chain length of up to 410 amino acids, a moderate molecular weight of 36kD, and non-repetitive splicing sequences to ensure 100% full human origin, with both high activity and high stability, while achieving a low sensitization rate, and can achieve high-concentration water-light products.
II. Raw material 2 - recombinant botulinum toxin under development
Through independent innovation, we have achieved a comprehensive breakthrough in molecular design and technology, achieved high biosafety, high expression and high toxicity activity, and possessed independent and complete intellectual property rights. Including type A and type E, we have successfully completed the strain screening and drugability research of recombinant type A botulinum toxin, and have obtained recombinant type A botulinum toxin with a purity of more than 97% and an activity of more than 2*107IU/mg. We are promoting it to enter clinical research.
Third, the third raw material - active peptide raw material
Recombinant cono peptide is also under intensive research and development.
Opening the international map Drawing a blueprint for the future
Although the exhibition has ended, the pursuit of new raw materials has not stopped. Yaohai Novagen Biology will continue to concentrate on scientific research, fully promote technological innovation, improve raw material quality and improve customer service experience, and inject young power into the sustainable development of the industry.
